List of Lybalvi drug patents
Lybalvi is owned by Alkermes Inc.
Lybalvi contains Olanzapine; Samidorphan L-Malate.
Lybalvi has a total of 10 drug patents out of which 0 drug patents have expired.
Lybalvi was authorised for market use on 28 May, 2021.
Lybalvi is available in tablet;oral dosage forms.
Lybalvi can be used as method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain, method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain, method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile; method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile, method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan.
Drug patent challenges can be filed against Lybalvi from 2025-05-28.
The generics of Lybalvi are possible to be released after 13 February, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7262298 | ALKERMES INC | 4-hydroxybenzomorphans |
Nov, 2025
(2 years from now) | |
| US9119848 | ALKERMES INC | Morphinan derivatives for the treatment of drug overdose |
Aug, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11185541 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(8 years from now) | |
| US9126977 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(8 years from now) | |
| US9517235 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(8 years from now) | |
| US10716785 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(8 years from now) | |
| US10300054 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(8 years from now) | |
| US11351166 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(8 years from now) | |
| US11241425 | ALKERMES INC | Composition for treating mental illness |
Aug, 2031
(8 years from now) | |
| US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 2025-05-28
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and sam...
Dosage: TABLET;ORAL
LYBALVI family patents
26
United States
6
Australia
6
Japan
6
European Union
3
Denmark
3
Slovenia
3
Portugal
3
Spain
3
Poland
3
Canada
2
Turkey
2
Russia
2
Lithuania
2
Hungary
2
Croatia
2
Cyprus
2
RS
2
New Zealand
1
Israel
1
Austria
1
Mexico
1
Norway
1
Brazil
1
Korea, Republic of
1
China
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic